https://feeds.newsfilecorp.com/company/12792 Latest news from Okogen, as distributed by TMX Newsfile. en CopyRight (c) 2026, Newsfile Corp. All Rights Reserved. office@newsfilecorp.com (Newsfile Corp.) office@newsfilecorp.com (Newsfile Corp.) Tue, 06 Oct 2026 09:29:44 -0400 https://images.newsfilecorp.com/logos/12792.jpg https://feeds.newsfilecorp.com/company/12792 https://www.newsfilecorp.com/release/317640/Okogen-Receives-CDSCO-Authorization-to-Advance-the-EMERALD-Phase-12-Study-of-Treyegen-OKG0303-for-Acute-Infectious-Conjunctivitis Plano, Texas--(Newsfile Corp. - October 6, 2026) - Okogen, Inc., a clinical-stage biotechnology company focused on developing innovative therapies for infectious diseases, today announced that the Central Drugs Standard Control Organisation (CDSCO), India's national drug regulatory authority, has authorized the EMERALD study, the Company's Phase 1/2 clinical trial evaluating Treyegen (OKG-0303) for the treatment of acute infectious conjunctivitis. To view the full...<img src="https://api.newsfilecorp.com/newsinfo/317640/156" id="156" width="2" height="2" style="width: 1px; height: 1px;border: 0px solid;" /> Tue, 06 Oct 2026 09:28:00 -0400 en https://www.newsfilecorp.com/release/317640